Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen

References

• Griffin M. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23S–9S.
   PubMedGoogle Scholar
• Naidu P, Booker L, Cravatt B, Lichtman A. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48–56.
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;46:791–6.
   PubMed Web of Science ®Google Scholar
• Sasso O, Bertorelli R, Bandiera T, et al. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res 2012;65:553–63.
   PubMed Web of Science ®Google Scholar
• Kinsey SG, Nomura DK, O'Neal ST, et al. Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 2011;338:795–802.
   PubMed Web of Science ®Google Scholar
• Crowe MS, Kinsey SG. MAGL inhibition modulates gastric secretion and motility following nsaid exposure in mice. Eur J Pharmacol 2017;807:198–204.
   PubMed Web of Science ®Google Scholar
• Sasso O, Migliore M, Habrant D, et al. Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage. Faseb J 2015;29:2616–27.
   PubMed Web of Science ®Google Scholar
• Migliore M, Habrant D, Sasso O, et al. Potent multitarget faah-cox inhibitors: design and structure-activity relationship studies. Eur J Med Chem 2016;109:216–37.
   PubMed Web of Science ®Google Scholar
• Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. Substrate-selective cox-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci 2014;35:358–67.
   PubMed Web of Science ®Google Scholar
• Goodman MC, Xu S, Rouzer CA, et al. Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site. J Biol Chem 2018;293:3028–38.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Tiger G, Stenström A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J Pharmacol Exp Ther 1997;283:729–34.
   PubMed Web of Science ®Google Scholar
• Cocco M, Congiu C, Onnis V, et al. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem 2003;38:513–8.
   PubMed Web of Science ®Google Scholar
• Holt S, Paylor B, Boldrup L, et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol 2007;565:26–36.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Björklund E, Lichtman AH, et al. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem 2013;28:172–82.
   PubMed Web of Science ®Google Scholar
• Karlsson J, Morgillo CM, Deplano A, et al. Interaction of the n-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and ibuprofen with FAAH: enantiomeric selectivity and binding mode. PLoS One 2015;10:e0142711.
   PubMed Web of Science ®Google Scholar
• Deplano A, Morgillo CM, Demurtas M, et al. Novel propanamides as fatty acid amide hydrolase inhibitors. Eur J Med Chem 2017;136:523–42.
   PubMed Web of Science ®Google Scholar
• Deplano A, Cipriano M, Moraca F, et al. Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors. J Enzyme Inhib Med Chem 2019;34:562–76.
   PubMed Web of Science ®Google Scholar
• Adams AD, Jones AB, Berger JP, et al. Preparation of 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders, Patent WO2002064094A2,2002.
   Google Scholar
• Windsor MA, Hermanson DJ, Kingsley PJ, et al. Substrate-selective inhibition of cyclooxygenase-2: development and evaluation of achiral profen probes. ACS Med Chem Letts 2012;3:759–63.
   PubMed Web of Science ®Google Scholar
• Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ. A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods 2004;60:171–7.
   PubMedGoogle Scholar
• Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610–4.
   PubMed Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aid Mol Des 2013;27:221–34.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2019-1: Maestro, New York, NY: Schrödinger, LLC, 2019.
   Google Scholar
• Palermo G, Rothlisberger U, Cavalli A, De Vivo M. Computational insights into function and inhibition of fatty acid amide hydrolase. Eur J Med Chem 2015;91:15–26.
   PubMed Web of Science ®Google Scholar
• Bracey M, Hanson MA, Masuda KR, et al. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002;298:1793–6.
   PubMed Web of Science ®Google Scholar
• Lodola A, Castelli R, Mor M, Rivara S. Fatty acid amide hydrolase inhibitors: a patent review (2009–2014). Expert Opin Ther Pat 2015;25:1247–66.
   PubMed Web of Science ®Google Scholar
• Shelley JC, Cholleti A, Frye L, et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J Comp Aided Mol Design 2007; 21:681–91.
   PubMed Web of Science ®Google Scholar
• Grippo L, Lucidi S. A globally convergent version of the Polak-Ribière conjugate gradient method. Math Program 1997; 78:375–91.
   Web of Science ®Google Scholar
• Glide, version 7.1. New York, NY: Schrödinger, LLC, 2019.
   Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47:1739–49.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9.
   PubMed Web of Science ®Google Scholar
• Banks JL, Beard HS, Cao Y, et al. Integrated modeling program, applied chemical theory (IMPACT). J Comp Chem 2005;26:1752–80.
   PubMed Web of Science ®Google Scholar
• De Wael F, Muccioli GG, Lambert DM, et al. Chemistry around imidazopyrazine and ibuprofen: discovery of novel fatty acid amide hydrolase (FAAH) inhibitors. Eur J Med Chem 2010;45:3564–74.
   PubMed Web of Science ®Google Scholar
• Favia AD, Habrant D, Scarpelli R, et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem 2012;55:8807–26.
   PubMed Web of Science ®Google Scholar
• Karlsson J, Fowler CJ. Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen. PLoS One 2014;9:e103589.
   PubMed Web of Science ®Google Scholar
• Duggan KC, Hermanson DJ, Musee J, et al. (R)-profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol 2011;7:803–9.
   PubMed Web of Science ®Google Scholar
• Gustin DJ, Ma Z, Min X, et al. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Bioorg Med Chem Lett 2011;21:2492–6.
   PubMed Web of Science ®Google Scholar